The latest news: Pharmaceutical Company Starts First Human Trials For Cannabis Treatment For Brain Cancer I like the way this is set up. Although it is too small of a patient population to rely on (I hope they measure IDH1 mutations at the very least), it is a big step in the right direction. If it shows a benefit, then a larger study can be done. Study Results Show Dose-Intensified Temozolomide Chemotherapy in the Adjuvant Setting Does Not Improve Survival in Patients with GBM Apparently. the standard schedule is better than the dose intensive schedule for GBM patients using Temodar. However, what I would love to see is a trial comparing different lengths of treatment. This trial used up to 12 months of treatment. Overall survivals were about 6 months after they stopped using the Temodar in either arm. Doesn't make sense to me to stop at 1 year. Musella Foundation will be out of the office next week! BrainTumor Co-Payment Assistance Program Status: OPEN to new applicants
